Medicine

Prof Michael O'Dwyer

MB, BCH, BAO (Hons) MRCPI, MRCPATH

Contact Details

Biomedical Sciences
NUI Galway
Corrib Village, Upper Newcastle
Galway
T: (091) 49 4443
E: michael.odwyer@nuigalway.ie
https://www.linkedin.com/profile/preview?locale=en_US&trk=prof-0-sb-preview-primary-button

Biography

Peer Reviewed Journals

	Year	Publication
	(2015)	'Drugging the unfolded protein response in acute leukemias' Kharabi Masouleh B, Chevet E;Panse J;Jost E;O'Dwyer M;Bruemmendorf TH;Samali A (2015) 'Drugging the unfolded protein response in acute leukemias'. Journal Of Hematology & Oncology, 8 [DOI] [Details]
	(2015)	'Neurotrophins and B-cell malignancies' Hillis J, O'Dwyer M, Gorman AM. (2015) 'Neurotrophins and B-cell malignancies'. Cellular And Molecular Life Sciences, [ARAN Link] [Details]
	(2015)	'Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia' Burger, JA,Tedeschi, A,Barr, PM,Robak, T,Owen, C,Ghia, P,Bairey, O,Hillmen, P,Bartlett, NL,Li, J,Simpson, D,Grosicki, S,Devereux, S,McCarthy, H,Coutre, S,Quach, H,Gaidano, G,Maslyak, Z,Stevens, DA,Janssens, A,Offner, F,Mayer, J,O'Dwyer, M,Hellmann, A,Schuh, A,Siddiqi, T,Polliack, A,Tam, CS,Suri, D,Cheng, M,Clow, F,Styles, L,James, DF,Kipps, TJ,RESONATE-2 Investigators (2015) 'Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia'. New England Journal Of Medicine, 373 :2425-2437 [DOI] [Details]
	(2015)	'G2/M arrest sensitises erythroid leukemia cells to TRAIL-induced apoptosis' Cruet-Hennequart, S, Paavilainen T, O'Dwyer, M, Toth R, Carty, MP, Samali, A, Szegezdi, E (2015) 'G2/M arrest sensitises erythroid leukemia cells to TRAIL-induced apoptosis'. Journal of Leukemia, [Details]
	(2014)	'A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response' FitzGerald J, Murillo LS, O'Brien G, O'Connell E, O'Connor A, Wu K, Wang GN, Rainey MD, Natoni A, Healy S, O'Dwyer M, Santocanale C (2014) 'A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response'. Plos One, 9 (6) [DOI] [Details]
	(2014)	'The Role of Inflammation in Leukaemia' Krawczyk, J,O'Dwyer, M,Swords, R,Freeman, C,Giles, FJ,Aggarwal, BB,Sung, B,Gupta, SC (2014) 'The Role of Inflammation in Leukaemia'. Advances In Tnf Family Research, 816 :335-360 [DOI] [Details]
	(2014)	'A High Through-Put Screen for Small Molecules Modulating MCM2 Phosphorylation Identifies Ryuvidine as an Inducer of the DNA Damage Response' FitzGerald, J,Murillo, LS,O'Brien, G,O'Connell, E,O'Connor, A,Wu, K,Wang, GN,Rainey, MD,Natoni, A,Healy, S,O'Dwyer, M,Santocanale, C (2014) 'A High Through-Put Screen for Small Molecules Modulating MCM2 Phosphorylation Identifies Ryuvidine as an Inducer of the DNA Damage Response'. Plos One, 9 [DOI] [Details]
	(2013)	'A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia' Maung, SW,Leahy, M,O'Leary, HM,Khan, I,Cahill, MR,Gilligan, O,Murphy, P,McPherson, S,Jackson, F,Ryan, M,Hennessy, B,McHugh, J,Goodyer, M,Bacon, L,O'Gorman, P,Nee, A,O'Dwyer, M,Enright, H,Saunders, J,O'Keeffe, D (2013) 'A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia'. British Journal Of Haematology, 163 :118-122 [DOI] [Details]
	(2013)	'Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models' Natoni A, Coyne MR, Jacobsen A, Rainey MD, O'Brien G, Healy S, Montagnoli A, Moll J, O'Dwyer M, Santocanale C (2013) 'Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models'. Cancers, 5 (3):901-918 [DOI] [Details]
	(2013)	'Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma' Vincenz L, JÃ¤ger R, O'Dwyer M, Samali A (2013) 'Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma'. Molecular Cancer Therapeutics, 12 (6):831-843 [DOI] [Details]
	(2013)	'Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma' Vincenz, L,Jager, R,O'Dwyer, M,Samali, A (2013) 'Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma'. Molecular Cancer Therapeutics, 12 (6):831-843 [DOI] [Details]
	(2013)	'Flushing out the diagnosis' Geoghegan, P,Moran, P,Sexton, DJ,O'Reilly, MW,O'Dwyer, M,O'Regan, A (2013) 'Flushing out the diagnosis'. Qjm-An International Journal Of Medicine, 106 :1121-1122 [DOI] [Details]
	(2012)	'Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder' Bourke, MG,Martin, ST,O'Dwyer, M,Hanaghan, J,Bennani, F,Barry, MK (2012) 'Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder'. Irish Journal Of Medical Science, 181 :285-287 [DOI] [Details]
	(2011)	'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia' McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer (2011) 'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia'. Leuk Lymphoma, 52 (5):919-921 [Details]
	(2011)	'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis' Dijk Mv, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A, Szegezdi E (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis'. Cancers, 3 (1):1329-1350 [DOI] [Details]
	(2011)	'Targeting AML through DR4 with a novel variant of rhTRAIL' Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ, Samali A (2011) 'Targeting AML through DR4 with a novel variant of rhTRAIL'. Journal Of Cellular And Molecular Medicine, 15 (10):2216-2231 [DOI] [Details]
	(2011)	'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic' Van Dijk M, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A and Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic'. Differentiation to TRAIL Mediated Apoptosis Cancers, 3 (1):1329-1350 [DOI] [Details]
	(2011)	'Mechanisms of action of a dual Cdc7/Cdc9 kinase inhibitor against quiescent and proliferating CLL cells' Natoni, A; Murillo, LS; Kliszak, AE; Catherwood, MA; Montagnoli, A; Samali, A; O'Dwyer, M; Santocanale, C (2011) 'Mechanisms of action of a dual Cdc7/Cdc9 kinase inhibitor against quiescent and proliferating CLL cells'. Molecular Cancer Therapeutics, 10 :1624-1634 [Details]
	(2011)	'Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells' Natoni, A,Murillo, LS,Kliszczak, AE,Catherwood, MA,Montagnoli, A,Samali, A,O'Dwyer, M,Santocanale, C (2011) 'Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells'. Molecular Cancer Therapeutics, 10 :1624-1634 [DOI] [ARAN Link] [Details]
	(2011)	'Targeting AML through DR4 with a novel variant of rhTRAIL' Szegezdi, E,Reis, CR,van der Sloot, AM,Natoni, A,O'Reilly, A,Reeve, J,Cool, RH,O'Dwyer, M,Knapper, S,Serrano, L,Quax, WJ,Samali, A (2011) 'Targeting AML through DR4 with a novel variant of rhTRAIL'. Journal Of Cellular And Molecular Medicine, 15 :2216-2231 [DOI] [Details]
	(2010)	'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia' Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800 [DOI] [Details]
	(2010)	'Home administration of bortezomib: Making a difference to myeloma patients' lives' Meenaghan, T,O'Dwyer, M,Hayden, P,Hayat, A,Murray, M,Dowling, M (2010) 'Home administration of bortezomib: Making a difference to myeloma patients' lives'. European Journal Of Oncology Nursing, 14 :134-136 [DOI] [ARAN Link] [Details]
	(2010)	'Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia' Swords, RT,Kelly, KR,Smith, PG,Garnsey, JJ,Mahalingam, D,Medina, E,Oberheu, K,Padmanabhan, S,O'Dwyer, M,Nawrocki, ST,Giles, FJ,Carew, JS (2010) 'Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 :3796-3800 [DOI] [Details]
	(2010)	'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010' Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103 [DOI] [Details]
	(2010)	'Clofarabine in the treatment of poor risk acute myeloid leukaemia' Krawczyk, J,Ansar, N,Swords, R,Murphy, T,MacDonagh, B,Meenaghan, T,Hayden, P,Hayad, A,Murray, M,O'Dwyer, M (2010) 'Clofarabine in the treatment of poor risk acute myeloid leukaemia'. Hematological Oncology, 28 :118-123 [DOI] [Details]
	(2010)	'administration of bortezomib: making a difference to myeloma patients' lives. Eur' Meenaghan T, O'Dwyer M, Hayden P, Hayat A, Murray M, Dowling M. Home (2010) 'administration of bortezomib: making a difference to myeloma patients' lives. Eur'. J Oncol Nurs, 14 (2):134-136 [Details]
	(2010)	'Cdc7 kinase - a new target for drug development' Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F (2010) 'Cdc7 kinase - a new target for drug development'. European Journal Of Cancer, 46 (1):33-40 [DOI] [Details]
	(2009)	'Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia' Giles FJ, O'Dwyer M, Swords R (2009) 'Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 23 (10):1698-1707 [DOI] [Details]
	(2009)	'CLOFARABINE IN THE TREATMENT OF POOR RISK ACUTE MYELOID LEUKAEMIA - GALWAY UNIVERSITY HOSPITAL EXPERIENCE' Krawczyk, J.,Ansar, N.,Murphy, T.,MacDonagh, B.,Meenaghan, T.,Swords, R.,Hayden, P.,Hayad, A.,Murray, M.,O'Dwyer, M. (2009) 'CLOFARABINE IN THE TREATMENT OF POOR RISK ACUTE MYELOID LEUKAEMIA - GALWAY UNIVERSITY HOSPITAL EXPERIENCE'. Haematologica-the Hematology Journal, 94 [Details]
	(2009)	'NOVEL TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE WITH LENALIDOMIDE' Krawczyk, J.,Murphy, T.,Swords, R.,Meenaghan, T.,O'Dwyer, M. (2009) 'NOVEL TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE WITH LENALIDOMIDE'. Haematologica-the Hematology Journal, 94 [Details]
	(2009)	'THERE IS NO PLACE LIKE HOME: A PILOT PROGRAM OF HOME ADMINISTRATION OF BORTEZOMIB AT GALWAY UNIVERSITY HOSPITAL' Meenaghan, T.,Krawczyk, J.,Hayat, A.,O'Dwyer, M.,Hayden, P. (2009) 'THERE IS NO PLACE LIKE HOME: A PILOT PROGRAM OF HOME ADMINISTRATION OF BORTEZOMIB AT GALWAY UNIVERSITY HOSPITAL'. Haematologica-the Hematology Journal, 94 [Details]
	(2009)	'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era' O'Dwyer, M,Atallah, E (2009) 'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era'. Seminars In Hematology, 46 :16-21 [DOI] [Details]
	(2006)	'TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt' Szegezdi, E,Cahill, S,Meyer, M,O'Dwyer, M,Samali, A (2006) 'TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt'. British Journal Of Cancer, 94 :398-406 [DOI] [Details]
	(2006)	'TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt' Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A (2006) 'TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt'. Br J Cancer, 94 (3):398-406 [DOI] [Details]

Book Chapters

	Year	Publication
	(2013)	'A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization' Natoni A, O'Dwyer M, Santocanale C (2013) 'A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization' In: [DOI] [Details]

Conference Publications

	Year	Publication
	(2014)	*Irish Association for Cancer Research* Fitzgerald, J; Murillo, L; O’Brien, G; O’Connell, E; O’Connor, A; Wu, K; Wang, GN; Rainey, MD; Natoni, A; Healy, S; O’Dwyer, M; Santocanale, C (2014) A high through put screen identifies Ryuvidine as a modulator of Cdc7 dependent phosphorylation of MCM2 and an inducer of the DNA damage response Irish Association for Cancer Research [Details]
	(2013)	*Advanced Molecular Systems Ltd* O’Connor, L. Krawczyk, J., Keady, E., Mullen, C., Lahiff, S., Ahsan, B., Eltom, S., Khan, S., Saeed, K. A., Abdelrahmen, M., Hayat, A., Murray, M., Glynn, B., O’Dwyer, M., Smith, T.J. (2013) Pilot Study using Targeted Sequencing for identification of mutations in Exons 3-8 of the Human RUNx1 Gene in Patients with Myeloid Disorders Advanced Molecular Systems Ltd Belfast, N. Ireland, , 18-OCT-13 - 20-OCT-13 [Details]
	(2013)	*Haematological Association of Ireland Annual Conference* Lacey, T., Krawvzk, J. Mullen, C. Keady, E. Lahiff, S. Ahsan, B. Eltom, S. Khan, S. Saeed, K.A. Abdelrahmen, M. Hayat, A. Murray, M. Glynn, B. O’Dwyer, M. Smith, T.J. O'Connor, L. (2013) Real-Time PCR Assays for the Detection of MPL-W515L, MPL-W515K and JAK2-V617F Mutations in Patients with Myeloid Malignancies Haematological Association of Ireland Annual Conference Belfast, N.Ireland, , 18-OCT-13 - 20-OCT-13 [Details]
	(2013)	*Irish Association for Cancer Research* Murillo, L; Natoni, A; O’Connell, E; Fitzgerald, J; O’Dwyer, M; Santocanale, C (2013) Development of a High-Throughput Screening assay for the identification of compounds affecting Cdc7 dependent MCM helicase phosphorylation Irish Association for Cancer Research [Details]
	(2010)	*American Society of Hematology Meeting Abstract* Morrell, R. C.,Szegezdi, E.,Halpin-McCormick, A.,Cawley, K.,Samali, A.,O'Dwyer, M. (2010) The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia American Society of Hematology Meeting Abstract , pp.768-768 [Details]
	(2003)	*American Society of Hematology. Meeting Abstract* Cahill, S.,Szegezdi, E.,Samali, A.,O'Dwyer, M. (2003) Arsenic trioxide sensitizes leukemic cells to TRAIL-induced apoptosis American Society of Hematology. Meeting Abstract [Details]

Conference Contributions

	Year	Publication
	(2015)	Haematological Association of Ireland Annual Meeting, T Keaney, L O’Connor, J Krawczyk, M O’Dwyer, M Murray, A. Hayat, M Abdelrahman, B. Glynn, C Mullen, S. Lahiff, T.J. Smith (2015) Development of novel molecular assay for CALR mutations using hybridisation probes and melt curve analysis. [Poster Presentation], Haematological Association of Ireland Annual Meeting, Galway, Ireland , 16-OCT-15 - 17-OCT-15. [Details]
	(2014)	Haematology Association of Ireland Annual Conference, Keaney , T., O’Connor, T., Krawczyk, J., O’Dwyer, M., Murray, M., Hayat, A., Abdelrahman, M., Glynn, B., Mullen, C?., Lahiff, S., Smith, T.J. (2014) Development of novel molecular assay using hybridisation probes and melt curve analysis for CALR mutations in myeloproliferative neoplasms. [Conference Organising Committee Chairperson], Haematology Association of Ireland Annual Conference, Sligo, Ireland , 17-OCT-14 - 19-OCT-14. [Details]

Abstract

	Year	Publication
	(2015)	Dual inhibition of PIM and PI3-kinase by IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment. Best, G,Crassini, K,O'Neill, M,O'Dwyer, M,Mulligan, S (2015) Dual inhibition of PIM and PI3-kinase by IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment. Abstract [Details]
	(2015)	Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma. Keane, N,Reidy, M,Natoni, A,O'Dwyer, M (2015) Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma. Abstract [Details]
	(2015)	E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271. Natoni, A,Smith, TAG,Keane, N,Locatelli-Hoops, SC,Oliva, I,Fogler, WE,Magnani, JL,O'Dwyer, M (2015) E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271. Abstract [Details]
	(2015)	Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland. Maung, SW,McEllistrim, C,Hayat, A,Murray, M,O'Dwyer, M,Thornton, P,Groarke, E,O'Keeffe, D,Leahy, M,Burke, A,O'Gorman, P,Weldon, C,Crotty, G,Perera, MR,Burke, C,McHugh, J,Enright, H,Desmond, R (2015) Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland. Abstract [Details]
	(2015)	Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis. Ruggeri, K,Maguire, A,Schmitz, S,Haller, E,Walsh, C,Bowden, J,Kuhn, I,Khan, A,Cook, G,O'Dwyer, M (2015) Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis. Abstract [Details]
	(2015)	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naive CLL/SLL (RESONATE-2 (TM)). Tedeschi, A,Barr, PM,Robak, T,Owen, C,Ghia, P,Bairey, O,Hillmen, P,Bartlett, NL,Li, JY,Simpson, D,Grosicki, S,Devereux, S,McCarthy, H,Coutre, S,Quach, H,Gaidano, G,Maslyak, Z,Stevens, DA,Janssens, A,Offner, F,Mayer, J,O'Dwyer, M,Hellmann, A,Schuh, A,Siddiqi, T,Polliack, A,Tam, CS,Keating, M,Suri, D,Zhou, C,Clow, F,Styles, L,James, DF,Kipps, TJ,Burger, JA (2015) Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naive CLL/SLL (RESONATE-2 (TM)). Abstract [Details]
	(2015)	The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation. Reidy, M,VanDijk, M,O'Neill, M,O'Dwyer, M (2015) The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation. Abstract [Details]
	(2014)	Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation. Schey, S,Dhanasiri, S,Lee, D,Sternas, L,Yu, X,Zaki, MH,Elvidge, J,O'Dwyer, M (2014) Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation. Abstract [Details]
	(2013)	Portal Vein Thrombosis in Chronic Lymphocytic Leukaemia. Divilly, PM,O'Dwyer, M (2013) Portal Vein Thrombosis in Chronic Lymphocytic Leukaemia. Abstract [Details]
	(2010)	Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells. Santocanale, A,Natoni, A,Murillo, L,Catherwood, M,Montagnoli, A,Samali, A,O'Dwyer, M (2010) Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells. Abstract [Details]
	(2009)	NOVEL TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE WITH LENALIDOMIDE. Krawczyk, J,Murphy, T,Swords, R,Meenaghan, T,O'Dwyer, M (2009) NOVEL TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE WITH LENALIDOMIDE. Abstract [Details]
	(2009)	CLOFARABINE IN THE TREATMENT OF POOR RISK ACUTE MYELOID LEUKAEMIA - GALWAY UNIVERSITY HOSPITAL EXPERIENCE. Krawczyk, J,Ansar, N,Murphy, T,MacDonagh, B,Meenaghan, T,Swords, R,Hayden, P,Hayad, A,Murray, M,O'Dwyer, M (2009) CLOFARABINE IN THE TREATMENT OF POOR RISK ACUTE MYELOID LEUKAEMIA - GALWAY UNIVERSITY HOSPITAL EXPERIENCE. Abstract [Details]
	(2009)	THERE IS NO PLACE LIKE HOME: A PILOT PROGRAM OF HOME ADMINISTRATION OF BORTEZOMIB AT GALWAY UNIVERSITY HOSPITAL. Meenaghan, T,Krawczyk, J,Hayat, A,O'Dwyer, M,Hayden, P (2009) THERE IS NO PLACE LIKE HOME: A PILOT PROGRAM OF HOME ADMINISTRATION OF BORTEZOMIB AT GALWAY UNIVERSITY HOSPITAL. Abstract [Details]
	(2009)	Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]
	(2009)	A CASE SERIES OF SIXTH NERVE PALSY ASSOCIATED WITH INTRACRANIAL PLASMACYTOMA. Krawczyk, J,Meenaghan, T,Kelly, M,Ansar, N,Murphy, T,MacDonagh, B,Crotty, GM,Hayad, A,Murray, M,O'Dwyer, M,Hayden, P (2009) A CASE SERIES OF SIXTH NERVE PALSY ASSOCIATED WITH INTRACRANIAL PLASMACYTOMA. Abstract [Details]
	(2003)	Arsenic trioxide sensitizes leukemic cells to TRAIL-induced apoptosis. Cahill, S,Szegezdi, E,Samali, A,O'Dwyer, M (2003) Arsenic trioxide sensitizes leukemic cells to TRAIL-induced apoptosis. Abstract [Details]

Correction

	Year	Publication
	(2014)	The Role of Inflammation in Leukaemia (vol 816, pg 335, 2014). Krawczyk, J,O'Dwyer, M,Swords, R,Freeman, C,Giles, FJ,Aggarwal, BB,Sung, B,Gupta, SC (2014) The Role of Inflammation in Leukaemia (vol 816, pg 335, 2014). Correction [DOI] [Details]

Editorial

	Year	Publication
	(2013)	Perifosine - a new option in treatment of acute myeloid leukemia?. Krawczyk, J,Keane, N,Swords, R,O'Dwyer, M,Freeman, CL,Giles, FJ (2013) Perifosine - a new option in treatment of acute myeloid leukemia?. Editorial [DOI] [Details]
	(2013)	5-Azacytidine for the treatment of myelodysplastic syndromes. Krawczyk, J,Keane, N,Freeman, CL,Swords, R,O'Dwyer, M,Giles, FJ (2013) 5-Azacytidine for the treatment of myelodysplastic syndromes. Editorial [DOI] [Details]
	(2003)	Current use of imatinib in the treatment of chronic myeloid leukemia. O'Dwyer, M (2003) Current use of imatinib in the treatment of chronic myeloid leukemia. Editorial [Details]

Letter

	Year	Publication
	(2011)	Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. Langabeer, SE,McCarron, SL,Carroll, P,Kelly, J,O'Dwyer, M,Conneally, E (2011) Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. Letter [DOI] [Details]
	(2011)	A novel e8a2 BCR--ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Mccarron, SL,Kelly, J,Coen, N,Mccabe, S,Fay, M,O'Dwyer, M,Hayden, PJ,Langabeer, SE (2011) A novel e8a2 BCR--ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Letter [DOI] [Details]

Meeting

	Year	Publication
	(2011)	Atypical BCR-ABL1 transcript types in adult Ph-positive acute lymphoblastic leukaemia. Langabeer, SE,McCarron, SL,Kelly, J,O'Dwyer, M,Leahy, M,Hayden, PJ,Vandenberghe, E (2011) Atypical BCR-ABL1 transcript types in adult Ph-positive acute lymphoblastic leukaemia. Meeting [Details]
	(2010)	The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia. Morrell, RC,Szegezdi, E,Halpin-McCormick, A,Cawley, K,Samali, A,O'Dwyer, M (2010) The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia. Meeting [Details]
	(2010)	A MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY AND QUALITY OF LIFE STUDY OF LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA. Yong, K,Amor, AA,Browne, P,Cavenagh, J,Dodds, T,Greil, R,Horvath, N,Ludwig, H,O'Dwyer, M,Rocafiguera, AO,Prince, M,Taylor, K,Knight, R,Rosettani, B (2010) A MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY AND QUALITY OF LIFE STUDY OF LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA. Meeting [Details]
	(2010)	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. Conneally, E,Swords, RT,Giles, FJ,McMullin, MF,le Coutre, P,Langabeer, S,Wieczorkowska, M,McDowell, C,Moulton, B,Egan, K,O'Dwyer, M (2010) Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. Meeting [Details]
	(2010)	THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML). Carew, J,Swords, R,Kelly, K,Smith, P,Garnsey, J,Mahalingam, D,Medina, E,O'Dwyer, M,Oberheu, K,Nawrocki, S,Giles, F (2010) THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML). Meeting [Details]
	(2009)	ACTIVITY OF MLN4924, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME, IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA. Swords, T,Kelly, K,Smith, P,Mahalingam, D,O'Dwyer, M,Nawrocki, S,Giles, F,Carew, J (2009) ACTIVITY OF MLN4924, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME, IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA. Meeting [Details]
	(2009)	The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update. Morris, T,Oakervee, H,Kettle, P,Drake, M,Brunton, A,Cook, G,Leahy, M,O'Dwyer, M,Murray, M,Enright, H,McCloy, M,O'Gorman, P,Yong, K,O'Shea, T,Popat, R,Cavenagh, J (2009) The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update. Meeting [Details]
	(2009)	Bortezomib, adriamycin and dexamethasone for patients with refractory and relapsed myeloma - results from the PAD (Ireland) study. Morris, TCM,Kettle, P,Drake, M,Brunton, A,Cook, G,Leahy, M,O'Dwyer, M,Murray, M,Enright, H,McCloy, M,O'Gorman, P,Yong, K,O'Shea, T,Popat, R,Oakervee, H,Cavenagh, J (2009) Bortezomib, adriamycin and dexamethasone for patients with refractory and relapsed myeloma - results from the PAD (Ireland) study. Meeting [Details]
	(2009)	OVERCOMING DRUG RESISTANCE WITH SGI-1776: A NOVEL PIM KINASE INHIBITOR WITH POTENT PRECLINICAL ACTIVITY IN ACUTE MYELOID LEUKEMIA. Swords, T,Kelly, K,Mahalingam, D,O'Dwyer, M,Nawrocki, S,Giles, F,Carew, J (2009) OVERCOMING DRUG RESISTANCE WITH SGI-1776: A NOVEL PIM KINASE INHIBITOR WITH POTENT PRECLINICAL ACTIVITY IN ACUTE MYELOID LEUKEMIA. Meeting [Details]
	(2007)	PAD given at relapse is more effective than VAD given as induction therapy - Results of a phase II study. Morris, TC,Kettle, PJ,Drake, MB,Brunton, A,Cook, G,Leahy, M,O'Dwyer, M,Enright, H,O'Shea, T,Popat, R,Oakervee, H,Cavenagh, JD (2007) PAD given at relapse is more effective than VAD given as induction therapy - Results of a phase II study. Meeting [Details]
	(2007)	Pad in relapsed and refractory myeloma. a phase II study. Morris, TCM,Drake, M,Kettle, PJ,Brunton, A,Cook, G,Leahy, M,O'Dwyer, M,Enright, H,O'Shea, T,Popat, R,Cavenagh, J (2007) Pad in relapsed and refractory myeloma. a phase II study. Meeting [Details]
	(2006)	Bortezomib, adriamycin dexamethasone (PAD) combination therapies or patients with relapsed or refractory myeloma previously treated with VAD or VAD like therapy. Morris, TC,Drake, M,Kettle, PJ,Brunton, A,Cavenagh, JD,Oakervee, HE,O'Dwyer, M,Murray, M,O'Shea, T,Cook, G (2006) Bortezomib, adriamycin dexamethasone (PAD) combination therapies or patients with relapsed or refractory myeloma previously treated with VAD or VAD like therapy. Meeting [Details]

Reviews

	Year	Publication
	(2015)	Targeting the Pim kinases in multiple myeloma. Keane, NA,Reidy, M,Natoni, A,Raab, MS,O'Dwyer, M (2015) Targeting the Pim kinases in multiple myeloma. Reviews [DOI] [Details]
	(2015)	Drugging the unfolded protein response in acute leukemias. Masouleh, BK,Chevet, E,Panse, J,Jost, E,O'Dwyer, M,Bruemmendorf, TH,Samali, A (2015) Drugging the unfolded protein response in acute leukemias. Reviews [DOI] [Details]
	(2014)	AKT as a therapeutic target in multiple myeloma. Keane, NA,Glavey, SV,Krawczyk, J,O'Dwyer, M (2014) AKT as a therapeutic target in multiple myeloma. Reviews [DOI] [Details]
	(2010)	Clinical Utility of PET/CT in Lymphoma. Cronin, CG,Swords, R,Truong, MT,Viswanathan, C,Rohren, E,Giles, FJ,O'Dwyer, M,Bruzzi, JF (2010) Clinical Utility of PET/CT in Lymphoma. Reviews [DOI] [Details]
	(2010)	Cdc7 kinase - A new target for drug development. Swords, R,Mahalingam, D,O'Dwyer, M,Santocanale, C,Kelly, K,Carew, J,Giles, F (2010) Cdc7 kinase - A new target for drug development. Reviews [DOI] [Details]
	(2009)	Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Giles, FJ,O'Dwyer, M,Swords, R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Reviews [DOI] [Details]
	(2005)	Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Amadori, S,Fenaux, P,Ludwig, H,O'Dwyer, M,Sanz, M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Reviews [DOI] [Details]